| Colleen Patricia Colbridge, | |
|
101 E State St, Kennett Square, PA 19348-3109 | |
| (610) 444-6350 | |
| Not Available |
| Full Name | Colleen Patricia Colbridge |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 101 E State St, Kennett Square, Pennsylvania |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124316351 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Colleen Patricia Colbridge, 133 Summer Ridge Dr, Lansdale, PA 19446-6711 Ph: (215) 393-4694 | Colleen Patricia Colbridge, 101 E State St, Kennett Square, PA 19348-3109 Ph: (610) 444-6350 |
News Archive
Australian scientists have significantly advanced our understanding of dopamine release from nerve cells, findings that should speed the development of more effective drugs for treating Parkinson's Disease.
"Unless steps are taken to eliminate cholera from Haiti and the neighboring Dominican Republic, the disease will likely resurge and could even spread to other parts of the Caribbean, international health officials said Wednesday," CQ HealthBeat reports.
Government enthusiasm for the Private Finance Initiative (PFI) in the health service - private sector investment in hospital building projects - may be dropping because of its high cost, says an editorial in this week's British Medical Journal.
Individuals with major depressive disorder (MDD) often undergo multiple courses of antidepressant treatment during their lives. This is because the disorder can recur despite treatment and because finding the right medication for a specific individual can take time.
Millennium Pharmaceuticals today announced, in collaboration with Johnson & Johnson Pharmaceutical Research & Development, LLC, the initiation of VISTA (Velcadeas Initial Standard Therapy in multiple myeloma: Assessment with melphalan and prednisone), a multicenter, international phase III clinical trial of Velcadein combination with melphalan and prednisone versus melphalan and prednisone in patients with newly diagnosed multiple myeloma (MM) who are not transplant candidates.
› Verified 8 days ago
Amy Elizabeth Osborne, MS, CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 101 E State St, Kennett Square, PA 19348 Phone: 800-367-5690 | |
Cara Kelleher, M.S. SLP-CFY Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 101 E State St, Kennett Square, PA 19348 Phone: 814-447-3037 Fax: 814-447-5486 | |
Alyssa K Bartkus, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 101 E State St, Kennett Square, PA 19348 Phone: 800-243-4556 | |
L Nichols, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 101 E State St, Kennett Square, PA 19348 Phone: 800-728-8808 | |
Amanda Webber, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 101 E State St, Kennett Square, PA 19348 Phone: 610-925-4225 | |
Nomi Chayot, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 101 E State St, Kennett Square, PA 19348 Phone: 855-477-5627 |